Skip to main content
Premium Trial:

Request an Annual Quote

Abbott's MDx Sales Fall 8 Percent in Q3 as Total Revenues Decline Slightly

NEW YORK (GenomeWeb News) – Abbott today reported that its third-quarter revenues declined a fraction of one percent to $9.77 billion from $9.82 billion as the firm nears its planned split into two separate, publicly-traded companies.

It fell short of Wall Street's consensus estimate for revenues of $9.94 billion.

The Abbott Park, Ill.-based medical products giant reported an 8 percent drop in molecular diagnostics sales year over year to $102 million from $111 million. In the US its MDx sales fell to $47 million from $54 million, and in international markets its MDx sales declined to $55 million from $57 million year over year.

The firm reiterated its plans to launch more than 15 new molecular diagnostic products over the next few years, including several oncology, infectious disease, and companion diagnostic assays.

Abbott posted net earnings of $1.94 billion, or $1.21 per share, for the quarter, compared to $303 million, or $.19 per share, for Q3 2011. Excluding one-time items, its net income for the third quarter of 2012 was $1.30 per share and for 2011 was $1.18 per share. Analysts, on average, expected $1.28 for Q3 2012.

Miles White, chairman and CEO of Abbott, said in a statement that the firm remains on track to split on January 1, 2013. Abbott announced those plans, under which it will separate into two firms — one focused on diversified medical products and the other on research-based pharmaceuticals — a year ago.

The firm narrowed its EPS guidance for full-year 2012 to a range between $5.06 and $5.08 from an earlier range of between $5.00 and $5.10.

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.